Pharmaceuticals
06 April 2020 - Posted by: Tine Carmeliet
As in several other European countries, Belgium has a system in place to allow the temporary use of certain innovative medicines on the Belgian market when no reimbursement decision has been taken due to the therapeutic effectiveness of the medicine not yet being proven. This system of “managed entry agreements” is institutionalised through the so-called › Read More
On-going debate on new French Bill regarding online sale of medicines
02 April 2020 - Posted by: Eveline Van Keymeulen
On 5 February 2020, the French government introduced a wide-ranging Bill to the Senate, entitled “the acceleration and simplification of public action”, which deals with a variety of matters, including new provisions on e-commerce for medicinal products (Article 34). Currently, the online sale of medicines is highly regulated in France: only medicinal products that can › Read More
China’s life sciences industry remains opportune despite Covid-19 coronavirus
01 April 2020 - Posted by: David Shen
While the novel Covid-19 coronavirus is at the top of the agenda for businesses around the world, and for good reason, it is creating challenges for medical and healthcare systems and signalling fundamental change across the life sciences industry. Activity in China’s life sciences market remains high as one of the few sectors to › Read More
27 March 2020 - Posted by: Eveline Van Keymeulen
The French National Agency for Medicines and Health Products Safety (ANSM) recently announced the set-up of accelerated procedures for the assessment of Covid-19 treatments that are currently being developed. However, no further details regarding this accelerated procedure are publicly available. In the context of the pandemic, clinical trials for other treatments taking place in French › Read More
French Administrative Supreme Court annuls CEPS decision for market exclusivity reasons
23 March 2020 - Posted by: Eveline Van Keymeulen
On 5 February 2020, the French Administrative Supreme Court (Conseil d’Etat) annulled a decision from the Economic Committee for Health Products (CEPS) from 15 March 2018, considering that it negated the useful effect of the regulation applicable to orphan medicines. Under Article 8 of the Orphan Medicinal Products Regulation ((EC) No 141/2000), a manufacturer who › Read More